Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...